Please login to the form below

Not currently logged in
Email:
Password:

German partners find diabetes biomarker

Helmholtz Zentrum München and Boehringer Ingelheim have identified a biomarker for diabetes-relevant protein

Helmholtz Zentrum München and Boehringer Ingelheim have jointly identified a biomarker for diabetes-relevant protein.

The indicator will enable the pre-clinical testing of FABP4 inhibitors, therefore facilitating the selection of potentially effective substances. Studies on human subjects and mouse models show that the FABP4 protein could be a potential target protein for new drugs to treat diabetes mellitus and atherosclerosis.

The biomarker was found through the use of lipidomics and metabolomics. Scientists at the Helmholtz Zentrum München were the first to use the modern lipidomics technologies to successfully identify such functionally relevant biomarkers for FABP4.

Boehringer Ingelheim provided the necessary biological and indication-specific knowledge; the Helmholtz Zentrum München contributed expertise in metabolomics and bioinformatics.

The development of the biomarker for FABP4 was the pilot project for the collaborative research venture to identify functional biomarkers.

19th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...
A snapshot of… Exscientia
...

Infographics